Weekly Recap: China strategy shift and €110M one-time Q3 2026 charges

Fresenius Medical Care AG Sponsored ADR (XETR:FME) is refocusing its China strategy toward advanced in—center dialysis and critical care tech, exiting peritoneal dialysis and stopping 4008A production, and booking about €110M in Q3 2026 one—time charges tied to Care Enablement China.Previous Week R…